Pulmonary Arterial Hypertension [PAH] Market Size

2022-05-09 11:48:49 UTC | Healthcare & Pharmaceuticals

According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 11.5% from 2022 to 2027.

Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.

Browse 151 Market Data Tables and 112 Figures spread through 189 Pages and in-depth TOC on “Global Pulmonary Arterial Hypertension Market- Forecast to 2027’’ https://www.globalmarketestimates.com/market-report/pulmonary-arterial-hypertension-market-3787

United Therapeutics Corporation, Bayer, Gilead Sciences, Inc., Johnson & Johnson, Viatris Inc., GlaxoSmithKline, Sandoz Inc. (Novartis), Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Teva Pharmaceutical Industries Ltd, among others, are the key players in the pulmonary arterial hypertension market.

Drug Class Outlook (Revenue, USD Billion, 2022-2027)

· Endothelin Receptor Antagonists (ERAs)

· PDE - 5 Inhibitors

· Prostacyclin and Prostacyclin Analogs

· SGC Stimulators

Type Outlook (Revenue, USD Billion, 2022-2027)

· Branded

· Generics

Route of Administration Outlook (Revenue, USD Billion, 2022-2027)

· Oral

· Intravenous/ subcutaneous

· Inhalational

Regional Outlook (Revenue, USD Billion, 2022-2027)

North America

The U.S.
Canada
Mexico

Europe

Germany
UK
France
Spain
Italy
Rest of Europe

Asia Pacific

China
India
Japan
South Korea
Australia
Rest of APAC

Central & South America

Brazil
Argentina
Rest of CSA

Middle East & Africa

Saudi Arabia
UAE
Rest of MEA

Contact: Yash Jain

Email address: yash.jain@globalmarketestimates.com

Phone Number: +1 6026667238